Cost-Effectiveness of dapagliflozin versus acarbose as a monotherapy in type 2 diabetes in China

PLoS ONE

Volumn 11, Issue 11, 2016, Pages

  Gu, Shuyan ^a   Mu, Yiming ^b   Zhai, Suodi ^c   Zeng, Yuhang ^a   Zhen, Xuemei ^a   Dong, Hengjin ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; DAPAGLIFLOZIN; GLIMEPIRIDE; INSULIN; METFORMIN; PLACEBO; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ARTICLE; CHINA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GENITAL TRACT INFECTION; HEALTH INSURANCE; HUMAN; HYPOGLYCEMIA; META ANALYSIS; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; SYSTEMATIC REVIEW; URINARY TRACT INFECTION; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; ECONOMIC MODEL; ECONOMICS; FEMALE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ACARBOSE; BENZHYDRYL COMPOUNDS; CHINA; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 84994669187     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0165629     Document Type: Article

References (103)

1. Chinese Diabetes Society. Chinese guideline for Type 2 diabetes prevention (2013). Chinese Journal of Diabetes. 2014; 22: 2-42.
2. International Diabetes Federation. IDF DIABETES ATLAS-Seventh Edition 2015. http://www. diabetesatlas.org/. Accessed January 21, 2016.
3. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013; 310: 948-959. doi: 10.1001/jama.2013.168118 PMID: 24002281
4. International Diabetes Federation. About diabetes: types of diabetes. Brussels, Belgium. http://www. idf.org/about-diabetes. Accessed January 21, 2016.
5. UK Prospective Diabetes Study UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853. PMID: 9742976
6. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317: 703-713. PMID: 9732337
7. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359: 1577-1589. doi: 10.1056/NEJMoa0806470 PMID: 18784090
8. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321: 405-412. PMID: 10938048
9. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012; 55: 1577-1596. doi: 10.1007/s00125-012-2534-0 PMID: 22526604
10. Freeman JS. Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs. J Am Osteopath Assoc. 2010; 110: 528-537. PMID: 20876838
11. Wang W, McGreevey WP, Fu C, Zhan S, Luan R, Chen W, et al. Type 2 diabetes mellitus in China: a preventable economic burden. Am J Manag Care. 2009; 15: 593-601. PMID: 19747024
12. Tang L, Chen X, Zhao H, Zhao L, Hu S. The financing burden of treatment of diabetes ? and Its symptom in urban China. Chinese Health Economics. 2003; 22: 21-23.
13. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2224-2260. doi: 10.1016/S0140-6736(12)61766-8 PMID: 23245609
14. World Health Organization. Comparative quantification of health risks: global and regional burden of disease attribution to selected major risk factors. http://www.who.int/healthinfo/global-burden- disease/cra/en/. Accessed January 21, 2016.
15. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014; 8: 330-339. doi: 10.1016/j.jash.2014.02.003 PMID: 24631482
16. Ji L, Hu D, Pan C, Weng J, Huo Y, Ma C, et al. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. Am J Med. 2013; 126: 911-925.
17. Centers for Disease Control and Prevention. Prevalence of overweight and obesity among adults with diagnosed diabetes-United States, 1988-1994 and 1999-2002. Morbidity and Mortality Weekly Report. 2004; 53: 1066-1068. PMID: 15549021
18. International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res Clin Pract. 2014; 104: 1-52. doi: 10.1016/j.diabres.2012.10.001 PMID: 24508150
19. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014; 37 Suppl 1: S14-S80.
20. Alvarez GF, Tofe PS, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab. 2008; 10 Suppl 1: 25-32.
21. Larkin AT, Hoffman C, Stevens A, Douglas A, Bloomgarden Z. Determinants of adherence to diabetes treatment. J Diabetes. 2015; 7: 864-871. doi: 10.1111/1753-0407.12264 PMID: 25565088
22. Pi-Sunyer FX. The Impact of Weight Gain on Motivation, Compliance, and Metabolic Control in Patients with Type 2 Diabetes Mellitus. POSTGRADUATE MEDICINE. 2009; 121: 94-107. doi: 10. 3810/pgm.2009.09.2056 PMID: 19820278
23. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. MEDICAL CARE. 2005; 43: 521-530. PMID: 15908846
24. Lundkvist J, Berne C, Bolinder B, Jonsson L. The economic and quality of life impact of hypoglycemia. The European journal of health economics. 2005; 6.
25. Sabale U, Ekman M, Granstrom O, Bergenheim K, McEwan P. Cost-effectiveness of dapagliflozin (Forxiga(R)) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Prim Care Diabetes. 2015; 9: 39-47. doi: 10.1016/j.pcd.2014.04.007 PMID: 24840612
26. Vivian EM. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. Am J Health Syst Pharm. 2015; 72: 361-372. doi: 10.2146/ajhp140168 PMID: 25694411
27. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009; 85: 513-519. doi: 10.1038/clpt.2008.250 PMID: 19129749
28. Parikh S, Wilding J, Jabbour S, Hardy E. Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. Int J Clin Pract. 2015; 69: 186-198. doi: 10.1111/ijcp.12531 PMID: 25438821
29. Bailey CJ, Morales VE, Woo V, Tang W, Ptaszynska A, List JF. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabet Med. 2015; 32: 531-541. doi: 10.1111/dme.12624 PMID: 25381876
30. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 375: 2223-2233. doi: 10.1016/S0140-6736(10)60407-2 PMID: 20609968
31. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011; 13: 928-938. doi: 10.1111/j. 1463-1326.2011.01434.x PMID: 21672123
32. Wilding JP, Norwood P, T'Joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009; 32: 1656-1662. doi: 10.2337/dc09-0517 PMID: 19528367
33. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012; 8: 495-502. doi: 10.1038/nrendo.2011.243 PMID: 22310849
34. Bailey CJ, Day C. SGLT2 inhibitors: glucuretic treatment for type 2 diabetes. The British Journal of Diabetes \& Vascular Disease. 2010; 10: 193-199.
35. Shi J, Fang Z, Lin Y. Meta-analysis on effects of dapagliflozin on hyperglycaemia and cardiovascular risk factors for patients with type 2 diabetes. The Chinese Journal of Clinical Pharmacology. 2015; 31: 116-118, 134.
36. Fioretto P, Giaccari A, Sesti G. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol. 2015; 14: 142. doi: 10.1186/s12933-015-0297-x PMID: 26474563
37. Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin T, Apanovitch AM, List JF. Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events. DRUG SAFETY. 2014; 37: 815-829. doi: 10.1007/s40264-014-0213-4 PMID: 25096959
38. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. International Journal of Clinical Practice. 2012; 66: 446-456. doi: 10.1111/j.1742-1241.2012.02911.x PMID: 22413962
39. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebocontrolled, phase 3 trial. Diabetes Care. 2010; 33: 2217-2224. doi: 10.2337/dc10-0612 PMID: 20566676
40. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009; 32: 650-657. doi: 10.2337/dc08-1863 PMID: 19114612
41. Kaku K, Inoue S, Matsuoka O, Kiyosue A, Azuma H, Hayashi N, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2013; 15: 432-440. doi: 10.1111/dom.12047 PMID: 23194084
42. Ji L, Ma J, Li H, Mansfield TA, T'Joen CL, Iqbal N, et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther. 2014; 36: 84-100. doi: 10.1016/j.clinthera.2013.11.002 PMID: 24378206
43. Kaku K, Kiyosue A, Inoue S, Ueda N, Tokudome T, Yang J, et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metab. 2014; 16: 1102-1110. doi: 10.1111/dom.12325 PMID: 24909293
44. AstraZeneca. Forxiga 5 mg & 10 mg film coated tablets- 4. Clinical particulars. Available at http:// www.medicines.org.uk/emc/medicine/27188/SPC/Forxiga+5mg++%26+10+mg+film+coated +tablets/. Accessed January 22, 2016.
45. Ji L, Lu J, Weng J, Jia W, Tian H, Zhu D, et al. China type 2 diabetes treatment status survey of treatment pattern of oral drugs users. J Diabetes. 2015; 7: 166-173. doi: 10.1111/1753-0407.12165 PMID: 24809622
46. Gu S, Shi J, Tang Z, Sawhney M, Hu H, Shi L, et al. Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis. PLoS One. 2015; 10: e126704.
47. Yang W, Liu J, Shan Z, Tian H, Zhou Z, Ji Q, et al. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2014; 2: 46-55. doi: 10.1016/S2213-8587(13)70021-4 PMID: 24622668
48. Gu S, Tang Z, Shi L, Sawhney M, Hu H, Dong H. Cost-Minimization Analysis of Metformin and Acarbose in Treatment of Type 2 Diabetes. Value in Health Regional Issues. 2015; 6: 84-88.
49. McEwan P, Peters JR, Bergenheim K, Currie CJ. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin. 2006; 22: 121-129. doi: 10.1185/030079906X80350 PMID: 16393438
50. McEwan P, Evans M, Bergenheim K. A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes Obes Metab. 2010; 12: 623-630. doi: 10.1111/j.1463-1326.2010.01198.x PMID: 20590737
51. McEwan P, Evans M, Kan H, Bergenheim K. Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. Diabetes Obes Metab. 2010; 12: 431-436. doi: 10.1111/j.1463-1326.2009.01184.x PMID: 20415691
52. McEwan P, Bergenheim K, Yuan Y, Tetlow AP, Gordon JP. Assessing the relationship between computational speed and precision: a case study comparing an interpreted versus compiled programming language using a stochastic simulation model in diabetes care. Pharmacoeconomics. 2010; 28: 665-674. doi: 10.2165/11535350-000000000-00000 PMID: 20524723
53. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004; 47: 1747-1759. doi: 10.1007/ s00125-004-1527-z PMID: 15517152
54. World Health Organization. The world health report 2002- Chapter 5 (Some Strategies to Reduce Risk- Technical considerations for cost-effectiveness analysis). http://www.who.int/whr/2002/en/ Chapter5.pdf?ua=1. Accessed January 24, 2016.
55. Hotta N, Kakuta H, Sano T, Matsumae H, Yamada H, Kitazawa S, et al. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study. Diabet Med. 1993; 10: 134-138. PMID: 8458189
56. Chan JC, Chan KW, Ho LL, Fuh MM, Horn LC, Sheaves R, et al. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group. Diabetes Care. 1998; 21: 1058-1061. PMID: 9653595
57. The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Available: http://www.cochrane-handbook.org. Accessed January 23, 2016.
58. Zhu Q, Tong Y, Wu T, Li J, Tong N. Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic metaanalysis. Clin Ther. 2013; 35: 880-899. doi: 10.1016/j.clinthera.2013.03.020 PMID: 23602502
59. Van de Laar F, Lucassen P, Akkermans R, Van de Lisdonk E, Rutten G, Van Weel C (2009) Alphaglucosidase inhibitors for type 2 diabetes mellitus (Review). pp. 1-180.
60. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997; 50: 683-691. PMID: 9250266
61. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, et al. Indirect comparisons of competing interventions. Health Technol Assess. 2005; 9: 1-134.
62. Wells GA, Sultan SA, Chen L, Khan M, Coyle D Indirect evidence: Indirect treatment comparisons in meta-analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health. 2009.
63. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003; 326: 472. doi: 10.1136/bmj.326.7387.472 PMID: 12609941
64. General Administration Of Sport Of China. National Physique Monitoring Bulletin (2014). http://www. sport.gov.cn/n16/n1077/n1227/7328132.html. Accessed January 24, 2016.
65. Worldwide Inflation Data. Average inflation China (CPI). http://www.inflation.eu/inflation-rates/china/ historic-inflation/cpi-inflation-china.aspxAccessed March 4, 2016.
66. The Organisation for Economic Co-operation and Development (OECD). Exchange rates. https:// data.oecd.org/conversion/exchange-rates.htm. Accessed October 6, 2016.
67. Gao L, Zhao FL, Li SC. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China. Int J Technol Assess Health Care. 2012; 28: 436-444. doi: 10. 1017/S0266462312000608 PMID: 23006540
68. Li H, Xu F, Wang F. Cost-effectiveness of biphasic insulin aspart 30 combined with metformin in patients with type 2 diabetes mellitus. Chinese Journal New Drugs. 2011; 20: 2163-2170.
69. Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, et al. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Adv Ther. 2008; 25: 752-774. doi: 10.1007/s12325-008-0080-4 PMID: 18704282
70. Zheng Y, Wu J, Xie K. Incidence and cost of hypoglycemia episode in patients with type 2 diabetes mellitus (T2DM). Chinese Rural Health Service Administration. 2012; 32: 1195-1198.
71. Meng H. Pharmacoeconomic analysis of the treatment of type 2 diabetes complicated with urinary infections with two different antibiotics. JOURNAL OF SHANDONG MIEICAL COLLEGE. 2009; 31: 91-93.
72. Marrett E, Radican L, Davies MJ, Zhang Q. Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: A survey study. BMC Res Notes. 2011; 4: 251. doi: 10.1186/1756-0500-4-251 PMID: 21777428
73. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in Type 2 diabetes. Diabet Med. 2008; 25: 245-254. doi: 10.1111/j.1464-5491.2007.02341.x PMID: 18215172
74. Guo H, Li J, Jiang Z. Follow-up effects of the increased physical activity on the glucolipid metabolic factors and medical costs in type 2 diabetic patients. CHINESE JOURNAL OF REHABILITATION MEDICINE. 2007; 22: 395-398.
75. Price Bureau. Official drug price list. http://www.zjpi.gov.cn/main/html/2013/CT10138/ 75fbbde9c06b496aba6490646b9ca77f.html. Accessed January 27, 2016.
76. Bank Of China BOC. Exchange Rate. http://www.boc.cn/sourcedb/whpj/. Accessed March 2, 2016.
77. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002; 22: 340-349. PMID: 12150599
78. Currie CJ, McEwan P, Peters JR, Patel TC, Dixon S. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health. 2005; 8: 581-590. doi: 10.1111/j.1524-4733.2005. 00046.x PMID: 16176496
79. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of healthrelated utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006; 22: 1523-1534. doi: 10.1185/030079906X115757 PMID: 16870077
80. Lane S, Levy AR, Mukherjee J, Sambrook J, Tildesley H. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. CURRENT MEDICAL RESEARCH AND OPINION. 2014; 30: 1267-1273.
81. Matza LS, Boye KS, Yurgin N, Brewster-Jordan J, Mannix S, Shorr JM, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res. 2007; 16: 1251-1265. doi: 10.1007/ s11136-007-9226-0 PMID: 17638121
82. Barry HC, Ebell MH, Hickner J. Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. J Fam Pract. 1997; 44: 49-60. PMID: 9010371
83. Caro JJ, Stillman IO, Danel A, Getsios D, McEwan P. Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model. Journal of Medical Economics. 2007; 10: 239-254.
84. National Bureau of Statistics of China. Gross Domestic Product (GDP) per capita. http://data.stats. gov.cn/easyquery.htm?cn=C01&zb=A0201&sj=2014. Accessed January 28, 2016.
85. Lee J, Ma S, Heng D, Chew S, Hughes K, Tai E. Hypertension, concurrent cardiovascular risk factors and mortality: the Singapore Cardiovascular Cohort Study. J Hum Hypertens. 2008; 22: 468-474. doi: 10.1038/jhh.2008.16 PMID: 18337755
86. Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NR. Cardiovascular outcomes in framingham participants with diabetes: the importance of blood pressure. Hypertension. 2011; 57: 891-897. doi: 10.1161/HYPERTENSIONAHA.110.162446 PMID: 21403089
87. Peters AL. Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk. Cleve Clin J Med. 2009; 76 Suppl 5: S20-S27.
88. Bodegard J, Sundstrom J, Svennblad B, Ostgren CJ, Nilsson PM, Johansson G. Changes in body mass index following newly diagnosed type 2 diabetes and risk of cardiovascular mortality: a cohort study of 8486 primary-care patients. Diabetes Metab. 2013; 39: 306-313. doi: 10.1016/j.diabet.2013. 05.004 PMID: 23871502
89. Bolin K, Gip C, Mork AC, Lindgren B. Diabetes, healthcare cost and loss of productivity in Sweden 1987 and 2005-a register-based approach. Diabet Med. 2009; 26: 928-934. doi: 10.1111/j.1464-5491.2009.02786.x PMID: 19719715
90. Yu AP, Wu EQ, Birnbaum HG, Emani S, Fay M, Pohl G, et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. CURRENT MEDICAL RESEARCH AND OPINION. 2007; 23: 2157-2169.
91. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011; 34: 1481-1486. doi: 10.2337/dc10-2415 PMID: 21593294
92. Zullig LL, Gellad WF, Moaddeb J, Crowley MJ, Shrank W, Granger BB, et al. Improving diabetes medication adherence: successful, scalable interventions. Patient Prefer Adherence. 2015; 9: 139-149. doi: 10.2147/PPA.S69651 PMID: 25670885
93. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. ARCHIVES OF INTERNAL MEDICINE. 2006; 166: 1836-1841. doi: 10.1001/archinte.166.17.1836 PMID: 17000939
94. White TJ, Vanderplas A, Chang E, Dezii CM, Abrams GD. The costs of non-adherence to oral antihyperglycemic medication in individuals with diabetes Mellitus and concomitant diabetes mellitus and cardiovascular disease in a managed care environment. DISEASE MANAGEMENT & HEALTH OUT-COMES. 2004; 12: 181-188.
95. Currie CJ, Peyrot M, Morgan CL, Poole CD, Jenkins-Jones S, Rubin RR, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012; 35: 1279-1284. doi: 10.2337/dc11-1277 PMID: 22511257
96. Miller BR, Nguyen H, Hu CJ, Lin C, Nguyen QT. New and emerging drugs and targets for type 2 diabetes: reviewing the evidence. Am Health Drug Benefits. 2014; 7: 452-463. PMID: 25558307
97. Tunceli K, Zhao C, Davies MJ, Brodovicz KG, Alexander CM, Iglay K, et al. Factors associated with adherence to oral antihyperglycemic monotherapy in patients with type 2 diabetes. Patient Prefer Adherence. 2015; 9: 191-197. doi: 10.2147/PPA.S71346 PMID: 25670888
98. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med. 2002; 19: 279-284. PMID: 11942998
99. Bayer. Glucobay 50mg tablets- 4. Clinical particulars. Available at http://www.medicines.org.uk/emc/ medicine/19972. Accessed February 8, 2016.
100. Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, et al. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective. BMC Health Serv Res. 2015; 15: 496. doi: 10. 1186/s12913-015-1139-y PMID: 26541516
101. Abad PE, Casado EP, Fernandez RJ, Morales EF, Betegon NL, Sanchez-Covisa J, et al. Cost-effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type-2 diabetes mellitus in Spain. Aten Primaria. 2015; 47: 505-513. doi: 10.1016/j. aprim.2014.11.002 PMID: 25555492
102. Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, et al. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus. Diabet Med. 2015; 32: 890-898. doi: 10.1111/dme.12772 PMID: 25817050
103. van Haalen HG, Pompen M, Bergenheim K, McEwan P, Townsend R, Roudaut M. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clin Drug Investig. 2014; 34: 135-146. doi: 10.1007/s40261-013-0155-0 PMID: 24243529